Read More

bluebird bio Saturday Highlighted New Data That Further Showed beti-cel Is A Potentially Curative 1-Time Gene Therapy For B-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable T1, Normal, Near-Normal Adult Hb Levels

Oral presentation featured in the ASH press program includes long-term data through August 2021 in patients who achieved transfusion independence (TI) (n=46) and remain transfusion-free through up to seven years of

BLUE